Detalles de la búsqueda
1.
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Clin Cancer Res
; 22(22): 5527-5538, 2016 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27780853
2.
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
J Med Chem
; 59(10): 4948-64, 2016 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27144831
3.
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Cancer Chemother Pharmacol
; 71(5): 1315-23, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23468082
4.
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Mol Cancer Ther
; 11(3): 690-9, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22238366
5.
Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
J Antibiot (Tokyo)
; 64(9): 649-54, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21792211
6.
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Chem Biol Drug Des
; 78(6): 999-1005, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22034911
7.
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Mol Cancer Ther
; 10(6): 1028-35, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21482694
8.
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
J Med Chem
; 53(12): 4701-19, 2010 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-20513156
Resultados
1 -
8
de 8
1
Próxima >
>>